# C9orf129 (Y-20): sc-245981



The Power to Question

# **BACKGROUND**

C9orf129 (chromosome 9 open reading frame 129) is a 196 amino acid protein encoded by a gene that maps to human chromosome 9q22.31. Chromosome 9 consists of about 145 million bases, represents 4% of the human genome and encodes nearly 900 genes. Thought to play a role in gender determination, deletion of the distal portion of 9p can lead to development of male to female sex reversal, the phenotype of a female with a male X,Y genotype. Hereditary hemorrhagic telangiectasia, which is characterized by harmful vascular defects, is associated with the chromosome 9 gene encoding endoglin protein, ENG. Familial dysautonomia is also associated with chromosome 9 though through the gene IKBKAP. Notably, chromosome 9 encompasses the largest interferon family gene cluster. Chromosome 9 is partnered with chromosome 22 in the translocation leading to the aberrant production of Bcr-Abl fusion protein often found in leukemias.

# **REFERENCES**

- Humphray, S.J., et al. 2004. DNA sequence and analysis of human chromosome 9. Nature 429: 369-374.
- 2. Coppo, P., et al. 2006. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br. J. Haematol. 134: 171-179.
- 3. Zheng, X., et al. 2006. BCR and its mutants, the reciprocal t(9;22)-associated Abl/Bcr fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer 7: 262.
- 4. Burmeister, T., et al. 2007. Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia. Haematologica 92: 1699-1702.
- Cottin, V., et al. 2007. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration 74: 361-378.
- Fernandez-L, A., et al. 2007. Gene expression fingerprinting for human hereditary hemorrhagic telangiectasia. Hum. Mol. Genet. 16: 1515-1533.
- Gardiner, J., et al. 2007. Potential role of tubulin acetylation and microtubule-based protein trafficking in familial dysautonomia. Traffic 8: 1145-1149.
- 8. Hims, M.M., et al. 2007. A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect. Genomics 90: 389-396.
- 9. Temtamy, S.A., et al. 2007. Phenotypic and cytogenetic spectrum of 9p trisomy. Genet. Couns. 18: 29-48.

# **CHROMOSOMAL LOCATION**

Genetic locus: C9orf129 (human) mapping to 9g22.31.

#### SOURCE

C9orf129 (Y-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of C9orf129 of human origin.

# **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### **PRODUCT**

Each vial contains 200  $\mu g$  lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-245981 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

# **APPLICATIONS**

C9orf129 (Y-20) is recommended for detection of C9orf129 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of C9orf129: 21 kDa.

# **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

# **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

### **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

**Santa Cruz Biotechnology, Inc.** 1.800.457.3801 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**